158 related articles for article (PubMed ID: 36975376)
21. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.
Whitsett TG; Cheng E; Inge L; Asrani K; Jameson NM; Hostetter G; Weiss GJ; Kingsley CB; Loftus JC; Bremner R; Tran NL; Winkles JA
Am J Pathol; 2012 Jul; 181(1):111-20. PubMed ID: 22634180
[TBL] [Abstract][Full Text] [Related]
22. PM
Morales-Rubio R; Amador-Muñoz O; Rosas-Pérez I; Sánchez-Pérez Y; García-Cuéllar C; Segura-Medina P; Osornio-Vargas Á; De Vizcaya-Ruiz A
Toxicology; 2022 Jan; 465():153026. PubMed ID: 34774659
[TBL] [Abstract][Full Text] [Related]
23. PML represses lung cancer metastasis by suppressing the nuclear EGFR-mediated transcriptional activation of MMP2.
Kuo HY; Huang YS; Tseng CH; Chen YC; Chang YW; Shih HM; Wu CW
Cell Cycle; 2014; 13(19):3132-42. PubMed ID: 25486572
[TBL] [Abstract][Full Text] [Related]
24. Oxidative stress-mediated epidermal growth factor receptor activation regulates PM
Wang G; Zhang G; Gao X; Zhang Y; Fan W; Jiang J; An Z; Li J; Song J; Wu W
Biochim Biophys Acta Gen Subj; 2020 Oct; 1864(10):129672. PubMed ID: 32562736
[TBL] [Abstract][Full Text] [Related]
25. PM2.5 Upregulates the Expression of MUC5AC via the EGFR-PI3K Pathway in Human Sinonasal Epithelial Cells.
Jiao J; Hu P; Li Y; Cai C; Wang X; Zhang L
Int Arch Allergy Immunol; 2022; 183(4):361-374. PubMed ID: 34736257
[TBL] [Abstract][Full Text] [Related]
26. PM
Deng X; Feng N; Zheng M; Ye X; Lin H; Yu X; Gan Z; Fang Z; Zhang H; Gao M; Zheng ZJ; Yu H; Ding W; Qian B
Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):112-125. PubMed ID: 27836757
[TBL] [Abstract][Full Text] [Related]
27. Lentinan Attenuated the PM2.5 Exposure-Induced Inflammatory Response, Epithelial-Mesenchymal Transition and Migration by Inhibiting the PVT1/miR-199a-5p/caveolin1 Pathway in Lung Cancer.
Qi H; Liu Y; Wang N; Xiao C
DNA Cell Biol; 2021 May; 40(5):683-693. PubMed ID: 33902331
[TBL] [Abstract][Full Text] [Related]
28. Fine Particulate Matter (PM
Chen Z; Ji N; Wang Z; Wu C; Sun Z; Li Y; Hu F; Wang Z; Huang M; Zhang M
J Biomed Nanotechnol; 2018 Dec; 14(12):2172-2184. PubMed ID: 30305224
[TBL] [Abstract][Full Text] [Related]
29. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
[TBL] [Abstract][Full Text] [Related]
30. Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.
Maity TK; Venugopalan A; Linnoila I; Cultraro CM; Giannakou A; Nemati R; Zhang X; Webster JD; Ritt D; Ghosal S; Hoschuetzky H; Simpson RM; Biswas R; Politi K; Morrison DK; Varmus HE; Guha U
Cancer Discov; 2015 May; 5(5):534-49. PubMed ID: 25735773
[TBL] [Abstract][Full Text] [Related]
31. Low-Dose Nicotine Activates EGFR Signaling via α5-nAChR and Promotes Lung Adenocarcinoma Progression.
Wang ML; Hsu YF; Liu CH; Kuo YL; Chen YC; Yeh YC; Ho HL; Wu YC; Chou TY; Wu CW
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957649
[TBL] [Abstract][Full Text] [Related]
32. Oxymatrine inhibits non-small cell lung cancer via suppression of EGFR signaling pathway.
Li W; Yu X; Tan S; Liu W; Zhou L; Liu H
Cancer Med; 2018 Jan; 7(1):208-218. PubMed ID: 29239135
[TBL] [Abstract][Full Text] [Related]
33. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
Chaib I; Karachaliou N; Pilotto S; Codony Servat J; Cai X; Li X; Drozdowskyj A; Servat CC; Yang J; Hu C; Cardona AF; Vivanco GL; Vergnenegre A; Sanchez JM; Provencio M; de Marinis F; Passaro A; Carcereny E; Reguart N; Campelo CG; Teixido C; Sperduti I; Rodriguez S; Lazzari C; Verlicchi A; de Aguirre I; Queralt C; Wei J; Estrada R; Puig de la Bellacasa R; Ramirez JL; Jacobson K; Ditzel HJ; Santarpia M; Viteri S; Molina MA; Zhou C; Cao P; Ma PC; Bivona TG; Rosell R
J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28376152
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of miR-32 activity promoted EMT induced by PM2.5 exposure through the modulation of the Smad1-mediated signaling pathways in lung cancer cells.
Yang D; Ma M; Zhou W; Yang B; Xiao C
Chemosphere; 2017 Oct; 184():289-298. PubMed ID: 28601662
[TBL] [Abstract][Full Text] [Related]
35. Fine particulate matter (PM2.5) induces inhibitory memory alveolar macrophages through the AhR/IL-33 pathway.
Liu Y; Yuan Q; Zhang X; Chen Z; Jia X; Wang M; Xu T; Wang Z; Jiang J; Ma Q; Zhang M; Huang M; Ji N
Cell Immunol; 2023 Apr; 386():104694. PubMed ID: 36871457
[TBL] [Abstract][Full Text] [Related]
36. RHBDD1 promotes proliferation, migration, invasion and EMT in renal cell carcinoma via the EGFR/AKT signaling pathway.
Li M; Cai L; Wang X; Yu Y; Jian W; Bao G; Gao Z; Guo J; Zhang J; Li C; Zhang C
Mol Med Rep; 2021 Dec; 24(6):. PubMed ID: 34581421
[TBL] [Abstract][Full Text] [Related]
37. Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.
Younes M; Wu Z; Dupouy S; Lupo AM; Mourra N; Takahashi T; Fléjou JF; Trédaniel J; Régnard JF; Damotte D; Alifano M; Forgez P
Oncotarget; 2014 Sep; 5(18):8252-69. PubMed ID: 25249545
[TBL] [Abstract][Full Text] [Related]
38. Ambient fine particulate matter inhibits 15-lipoxygenases to promote lung carcinogenesis.
Li MY; Liu LZ; Li W; Ng CSH; Liu Y; Kong AWY; Zhao Z; Wang S; Qi H; Jia H; Yang S; Du J; Long X; Ho RLK; Chak ECW; Wan IYP; Mok TSK; Underwood MJ; Gali NK; Ning Z; Chen GG
J Exp Clin Cancer Res; 2019 Aug; 38(1):359. PubMed ID: 31420013
[TBL] [Abstract][Full Text] [Related]
39. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.
Tang Z; Du R; Jiang S; Wu C; Barkauskas DS; Richey J; Molter J; Lam M; Flask C; Gerson S; Dowlati A; Liu L; Lee Z; Halmos B; Wang Y; Kern JA; Ma PC
Br J Cancer; 2008 Sep; 99(6):911-22. PubMed ID: 19238632
[TBL] [Abstract][Full Text] [Related]
40. Desmoglein-2 modulates tumor progression and osimertinib drug resistance through the EGFR/Src/PAK1 pathway in lung adenocarcinoma.
Jin R; Wang X; Zang R; Liu C; Zheng S; Li H; Sun N; He J
Cancer Lett; 2020 Jul; 483():46-58. PubMed ID: 32272148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
